Tykerb
기본 정보
- CAS
388082-77-7- 표준 SMILES
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1- InChIKey
OZDXXJABMOYNGY-UHFFFAOYSA-N- 분자식
- C36H34ClFN4O7S2
- 평균 분자량
- 753.3 g/mol
- 단동위원소 질량
- 752.1541476
개요
See also: Lapatinib Ditosylate (annotation moved to); Lapatinib (annotation moved to).
이름 및 식별자
- 우선 이름
- Tykerb
- IUPAC
- N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid
- 영어명
- Lapatinib Ditosylate
- 분자식
- C36H34ClFN4O7S2
- 분자량
- 753.26
이름 및 동의어
LAPATINIB TOSYLATE1187538-35-7TykerbLapatinib (tosylate)CHEMBL1076241N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acidGW 282974XS1028N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-methylbenzenesulfonic acidMLS004774143orb1744815SCHEMBL1374543
이름 더 보기
GW-572016FTykerb Ditosylatapatinib DitosyLTykerb DitosylateTykerb(lapatinib)GW-572016 ditosylateGW 572016 ditosylateLapatinib ditosylateLapatinib ditasylate
SCHEMBL31732815EBC-35022HY-50898CNSC-727989SMR002544679CS-0009316EN300-200525284-methylbenzene-1-sulfonic acid; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
물성
구조 계산 물성
- 극성 표면적
- 177 Ų
- 수소 결합 공여자 수
- 3
- 수소 결합 수용자 수
- 12
- 회전 가능 결합 수
- 12
- 무거운 원자 수
- 51
- 형식 전하
- 0
- 복잡도
- 1,100
물리화학적 성질
- 녹는점
- 240 · 240-2420C
- 저장 조건
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- 용해도
- 24.3 mg/mL · ≥24.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
- 물리적 상태
- 고체
- 색상
- Light yellow to yellow
- 수용성
- Water: Insoluble
화학적 성질
Yellow Solid
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
안전 데이터
- HS 번호
- 29420000
- safety_code
- 24/25
화학 및 산업
응용 분야
개요Lapatinib, an ErB-1 and ErB-2 dual kinase inhibitor, was launched for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy. The drug was discovered and developed by GlaxoSmithKline and is also currently being evaluated for several additional cancer indications.
용도Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…